title: Percutaneous endoscopic gastrostomy in children with malignant disease.
abstract: The objective of the study was to assess both the possible complications of percutaneous endoscopic gastrostomy (PEG) in pediatric cancer patients and its effect on weight development. The medical records of 18 children with a median age of 2.5 years (range, 0.5-14.2 years) were reviewed. The diagnoses were leukemia, central nervous system tumors, solid tumors, and lymphoma. The indications for PEG were anticipated therapy-related nutritional problems and inadequate food intake, weight loss, swallowing problems in relation to paresis of the pharynx, and relapse of the disease. Ten children received a PEG at treatment start, and eight children received it at a median time of 3.4 months (range, 0.9-27.4 months) after treatment start. The median duration of having a PEG in place was 12.3 months (range, 1.2-24.0 months). At admission the median weight for age expressed as standard deviation (SD) was -0.11 (range, -2.78-2.68). There was a significant (p =.005) decrease in the median SD from admission until PEG installation. There was also a significant increase in the median SD from the start of PEG use until 1 (p =.04) and 2 (p =.039) months after start. The most common complications were episodes of inflammation of the PEG site, which were successfully treated with topically or orally administered antibiotics, and episodes of infection, which required intravenously administered antibiotics. Taking into consideration the medical condition of the children in the study group and the considerable length of time with a PEG in place, we believe that nutrition via PEG in children with cancer has several advantages and is rarely associated with other than minor complications.
authors.affiliation: Department of Clinical Science-Pediatrics, Umeå University, Umeå, Sweden.
authors.forename: Inger
authors.initials: I
authors.lastname: Skolin
authors.forename: Olle
authors.initials: O
authors.lastname: Hernell
authors.forename: Marita Vikström
authors.initials: MV
authors.lastname: Larsson
authors.forename: Chatrin
authors.initials: C
authors.lastname: Wahlgren
authors.forename: Ylva Britt
authors.initials: YB
authors.lastname: Wahlin
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D016543:Central Nervous System Neoplasms / Q000150:complications; D002648:Child; D002675:Child, Preschool; D016145:Endoscopy, Digestive System / Q000379:methods*; D005260:Female; D005774:Gastrostomy / Q000379:methods*; D006304:Health Status; D006801:Humans; D007223:Infant; D007249:Inflammation; D007938:Leukemia / Q000150:complications; D008223:Lymphoma / Q000150:complications; D008297:Male; D009748:Nutrition Disorders / Q000209:etiology / Q000628:therapy; D018529:Nutritional Support; D012189:Retrospective Studies; D016896:Treatment Outcome; D015430:Weight Gain
chemical_list: D000900:Anti-Bacterial Agents